RCRuth Cortado

Ruth Cortado

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ruth Cortado has a total of 60 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Distinct inflammatory marker profiles of adolescents and young adults among the HIV risk, infection, and treatment spectrum

    by Huan Vinh Dong, Gielenny M. Salem, Tara Kerin, Kwan Hou Tang, Ruth Cortado, Myung Shin-Sim, Elizabeth Mayfield Arnold, Dallas Swendeman, Nicole H. Tobin, Anne W. Rimoin, et al.

    Youth living with or at HIV-risk exhibit distinct immune perturbations during HIV exposure, infection, and antiretroviral therapy (ART). Understanding immune perturbations is critical for development of tailored prevention and enhanced therapeutic strategies. We performed plasma proteomic profiling of 49 biomarkers using Luminex multiplex assay in 262 participants (mean age of 21.9 years), including healthy controls, high-risk youth without HIV (HRY), newly diagnosed youth living with HIV (NY), and previously diagnosed youth on ART for over 24 months (PY), and report distinct immune landscapes. Among HRY, we observe dysregulation of circulating interferon-driven inflammation. NY display overt systemic inflammation at diagnosis, which partially resolves but does not fully normalize within 24 months of ART. PY display largely normalized immune profiles, though circulating signatures consistent with residual checkpoint activation persist. Our results identify conserved and stage-specific, circulating inflammatory modulators and key transcriptional regulators delineating HIV susceptibility, progression, and long-term treatment responses.

  • Open Access

    The systemic inflammatory landscape of COVID-19 in pregnancy: Extensive serum proteomic profiling of mother-infant dyads with in utero SARS-CoV-2

    by Suan-Sin Foo, Mary Catherine Cambou, Thalia Mok, Viviana M. Fajardo, Kyle L. Jung, Trevon Fuller, Weiqiang Chen, Tara Kerin, Jenny Mei, Debika Bhattacharya, et al.


  • Open Access

    Acute HIV Infection in Youth: Protocol for the Adolescent Trials Network 147 (ATN147) Comprehensive Adolescent Research and Engagement Studies (CARES) Study

    by Karin Nielsen-Saines, Kate Mitchell, Tara Kerin, Jasmine Fournier, Leslie Kozina, Brenda Andrews, Ruth Cortado, Robert Bolan, Risa Flynn, Mary Jane Rotheram, et al.

    Background: Early treatment studies have shown that prompt treatment of HIV with combination antiretroviral therapy (cART) can limit the size of latent viral reservoirs, thereby providing clinical and public health benefits. Studies have demonstrated that adolescents have a greater capacity for immune reconstitution than adults. Nevertheless, adolescents who acquired HIV through sexual transmission have not been included in early treatment studies because of challenges in identification and adherence to cART. Objective: This study aimed to identify and promptly treat with cART youth aged 12 to 24 years in Los Angeles and New Orleans who have acute, recent, or established HIV infection, as determined by Fiebig stages 1 to 6 determined by viral RNA polymerase chain reaction, p24 antigen presence, and HIV-1 antigen Western blot. The protocol recommends treatment on the day of diagnosis when feasible. Surveillance and dedicated behavioral strategies are used to retain them in care and optimize adherence. Through serial follow-up, HIV biomarkers and response to antiretroviral therapy (ART) are assessed. The study aims to assess viral dynamics, decay and persistence of viral reservoirs over time, and correlate these data with the duration of viral suppression. Methods: A total of 72 youth (36 acutely infected and 36 treatment naïve controls) are enrolled across clinical sites using a current community-based strategy and direct referrals. Youth are prescribed ART according to the standard of care HIV-1 management guidelines and followed for a period of 2 years. Assessments are conducted at specific time points throughout these 2 years of follow-up for monitoring of adherence to ART, viral load, magnitude of HIV reservoirs, and presence of coinfections. Results: The study began enrolling youth in July 2017 across study sites in Los Angeles and New Orleans. As of September 30, 2018, a total of 37 youth were enrolled, 12 with recently acquired, 16 with established HIV infection as determined by Fiebig staging, and 9 pending determination of Fiebig status. Recruitment and enrollment are ongoing. Conclusions: We hypothesize that the size of the HIV reservoir and immune activation markers will be different across groups treated with cART, that is, those with acute or recent HIV infection and those with established infection. Adolescents treated early who are virally suppressed will have diminished HIV reservoirs than those with established infection. These youth may be potential candidates for a possible HIV vaccine and additional HIV remission intervention trials. Our study will inform future studies of viral remission strategies. International Registered Report Identifier (IRRID): DERR1-10.2196/10807


  • Open Access

    Acute HIV Infection in Youth: Protocol for the Adolescent Trials Network 147 (ATN147) Comprehensive Adolescent Research and Engagement Studies (CARES) Study (Preprint)

    by Karin Nielsen-Saines, Kate Mitchell, Tara Kerin, Jasmine Fournier, Leslie Kozina, Brenda Andrews, Ruth Cortado, Robert Bolan, Risa Flynn, Mary Jane Rotheram, et al.

    BACKGROUND Early treatment studies have shown that prompt treatment of HIV with combination antiretroviral therapy (cART) can limit the size of latent viral reservoirs, thereby providing clinical and public health benefits. Studies have demonstrated that adolescents have a greater capacity for immune reconstitution than adults. Nevertheless, adolescents who acquired HIV through sexual transmission have not been included in early treatment studies because of challenges in identification and adherence to cART. OBJECTIVE This study aimed to identify and promptly treat with cART youth aged 12 to 24 years in Los Angeles and New Orleans who have acute, recent, or established HIV infection, as determined by Fiebig stages 1 to 6 determined by viral RNA polymerase chain reaction, p24 antigen presence, and HIV-1 antigen Western blot. The protocol recommends treatment on the day of diagnosis when feasible. Surveillance and dedicated behavioral strategies are used to retain them in care and optimize adherence. Through serial follow-up, HIV biomarkers and response to antiretroviral therapy (ART) are assessed. The study aims to assess viral dynamics, decay and persistence of viral reservoirs over time, and correlate these data with the duration of viral suppression. METHODS A total of 72 youth (36 acutely infected and 36 treatment naïve controls) are enrolled across clinical sites using a current community-based strategy and direct referrals. Youth are prescribed ART according to the standard of care HIV-1 management guidelines and followed for a period of 2 years. Assessments are conducted at specific time points throughout these 2 years of follow-up for monitoring of adherence to ART, viral load, magnitude of HIV reservoirs, and presence of coinfections. RESULTS The study began enrolling youth in July 2017 across study sites in Los Angeles and New Orleans. As of September 30, 2018, a total of 37 youth were enrolled, 12 with recently acquired, 16 with established HIV infection as determined by Fiebig staging, and 9 pending determination of Fiebig status. Recruitment and enrollment are ongoing. CONCLUSIONS We hypothesize that the size of the HIV reservoir and immune activation markers will be different across groups treated with cART, that is, those with acute or recent HIV infection and those with established infection. Adolescents treated early who are virally suppressed will have diminished HIV reservoirs than those with established infection. These youth may be potential candidates for a possible HIV vaccine and additional HIV remission intervention trials. Our study will inform future studies of viral remission strategies. INTERNATIONAL REGISTERED REPOR DERR1-10.2196/10807